2025 AMA Research Challenge – Member Premier Access

October 22, 2025

Virtual only, United States

Would you like to see your presentation here, made available to a global audience of researchers?
Add your own presentation or have us affordably record your next conference.

Background Normal pressure hydrocephalus (NPH) is commonly treated with ventriculoperitoneal shunting, though shunt revisions remain a frequent complication and wound dehiscence, albeit rare, may lead to full revision surgery. The Valve-Agnostic Cranial Implant (VACI, “InvisiShunt®” Longeviti, Inc.), is designed to countersink ventriculoperitoneal shunt valves, to reduce dehiscence and the need for revision. These were first implanted in 2019 and offer a low-profile alternative to traditional subgaleal shunt placement. However, only one prior clinical trial report of its use exists to date (n=25). This case series of twenty-five patients seeks to add to the existing literature on VACI efficacy in NPH patients. Methods Twenty-five patients diagnosed with NPH underwent implantation of the VACI (InvisiShunt®), at a mean age of 76.4 ± 10.1 years. This case series was conducted at Hoag Medical Center, Newport Beach, CA, USA, from November 2022 to March 2023. Follow-up ranged from 4 to 24 months. Patient demographics, comorbidities, preoperative symptoms, surgical details, postoperative outcomes, and complications were collected and analyzed. Results No intraoperative complications occurred. Six patients demonstrated either altered mental status, abdominal pain, or generalized weakness, unrelated to the implant. There were no infections reported within the 30-day post-operative period and up to 24 months of follow-up. There was one incidence of wound dehiscence that necessitated full revision surgery. Patients underwent an average of 2.3 ± 1.4 reprogramming events. Post-operative outcomes included improvements in gait disturbance (n=18; 72.0%) and urinary incontinence (n=9; 36.0%), and cognitive disturbances (n=8; 32%). Conclusion Our findings support the potential of VACI as a viable and safe low-profile alternative to traditional subgaleal shunt valve placement for NPH treatment, with no increase in morbidity. Further research with extended follow-up is needed to confirm these preliminary results and evaluate long-term efficacy.

Next from 2025 AMA Research Challenge – Member Premier Access

Sweet Troubles in AML: Sequential Histiocytoid Sweet Syndrome Triggered by Hypomethylating Therapy

Sweet Troubles in AML: Sequential Histiocytoid Sweet Syndrome Triggered by Hypomethylating Therapy

2025 AMA Research Challenge – Member Premier Access

Masoud Harati

22 October 2025